Assessing MicroRNA-375 Levels in Type 2 Diabetes Mellitus (T2DM) Patients and Their First-Degree Relatives with T2DM

Overview

Journal Diabetes Metab Syndr Obes

Publisher Dove Medical Press

Specialty Endocrinology

Date 2021 Apr 7

PMID 33824598

Citations 11

Authors

Xu Wu

Yashan Li

Baohua Man

Dexuan Li

Affiliations

Soon will be listed here.

Abstract

Purpose: The pancreatic islet specific microRNA-375 (miR-375) is overexpressed in type 2 diabetes mellitus (T2DM) patients suppressing the glucose-induced insulin secretion. Thus, miR-375 may serve as a biomarker for the early prediction of T2DM among high-risk individuals. We conducted this clinical study to assess the significance of miR-375 among type 2 diabetes mellitus (T2DM) patients and their first-degree relatives.

Patients And Methods: We included 56 Han Chinese individuals (N: NGT = 21, T2DM = 10, FD-NGT =13 and FD-T2DM = 12) who received medical health check-ups from January 2018 to September 2018 at The Third Hospital of Yunnan Province, China. They were categorized as normal glucose tolerance (NGT), T2DM, first-degree relatives with normal glucose tolerance (FD-NGT) and first-degree relatives with T2DM (FD-T2DM). OGTT, C-peptide and Insulin tests were performed to confirm the diagnosis. The miR-375 levels were determined by Quantitative real-time RT-PCR (qRT-PCR).

Results: The OGTT test showed a significant difference in T2DM and FD-T2DM groups compared with NGT and FD-NGT (p< 0.05). Similar results were observed during C-peptide and insulin tests. Interestingly, the 2-hour insulin test showed FD-NGT group having a significantly higher mean ± standard error of (64.240 ± 12.775) compared to NGT (28.836 ± 10.875). Assessment of miR-375 expression levels in 4 groups showed a significant up-regulation in T2DM and FD-T2DM compared with NGT and FD-NGT groups. A slight increase in miRNA expression was observed in FD-NGT compared with NGT group but was not statistically significant.

Conclusion: The OGTT, C-peptide and insulin tests revealed a statistically significant difference in T2DM and FD-T2DM compared with NGT and FD-NGT groups. A significantly higher miR-375 expression was also observed in T2DM and FD-T2DM groups compared with NGT and FD-NGT and thus, miR-375 may serve as a stable biomarker for the early prediction of T2DM among high-risk individuals.

Citing Articles

Novel Micro-Ribonucleic Acid Biomarkers for Early Detection of Type 2 Diabetes Mellitus and Associated Complications-A Literature Review.

Ahmed S, Adnan H, Khawaja M, Butler A Int J Mol Sci. 2025; 26(2).

PMID: 39859467 PMC: 11765584. DOI: 10.3390/ijms26020753.

Gestational Diabetes Mellitus: Unveiling Maternal Health Dynamics from Pregnancy Through Postpartum Perspectives.

Mora-Ortiz M, Rivas-Garcia L Open Res Eur. 2024; 4:164.

PMID: 39355538 PMC: 11443192. DOI: 10.12688/openreseurope.18026.1.

Evaluation of circulating plasma miR-9, miR-29a, miR-192, and miR-375 as potential biomarkers for predicting prediabetes and type 2 diabetes in Nepali adult population.

Pokharel D, Maskey A, Kafle R, Batajoo A, Dahal P, Raut R Noncoding RNA Res. 2024; 9(4):1324-1332.

PMID: 39104712 PMC: 11298881. DOI: 10.1016/j.ncrna.2024.07.001.

Dysregulated microRNAs in type 2 diabetes and breast cancer: Potential associated molecular mechanisms.

Improta-Caria A, Ferrari F, Gomes J, Villalta P, Soci U, Stein R World J Diabetes. 2024; 15(6):1187-1198.

PMID: 38983808 PMC: 11229979. DOI: 10.4239/wjd.v15.i6.1187.

Multireceptor Analysis for Evaluating the Antidiabetic Efficacy of Karanjin: A Computational Approach.

Nag S, Stany B, Mishra S, Kumar S, Mohanto S, Ahmed M Endocrinol Diabetes Metab. 2024; 7(4):e509.

PMID: 38982323 PMC: 11233261. DOI: 10.1002/edm2.509.

References

Zhu H, Fan G . Extracellular/circulating microRNAs and their potential role in cardiovascular disease. Am J Cardiovasc Dis. 2011; 1(2):138-149. PMC: 3207246. View

Fransquet P, Ryan J . Micro RNA as a potential blood-based epigenetic biomarker for Alzheimer's disease. Clin Biochem. 2018; 58:5-14. DOI: 10.1016/j.clinbiochem.2018.05.020. View

Kim V, Han J, Siomi M . Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol. 2009; 10(2):126-39. DOI: 10.1038/nrm2632. View

Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N . Serum microRNAs are promising novel biomarkers. PLoS One. 2008; 3(9):e3148. PMC: 2519789. DOI: 10.1371/journal.pone.0003148. View

Wojciechowska A, Braniewska A, Kozar-Kaminska K . MicroRNA in cardiovascular biology and disease. Adv Clin Exp Med. 2017; 26(5):865-874. DOI: 10.17219/acem/62915. View

Poy M, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, MacDonald P . A pancreatic islet-specific microRNA regulates insulin secretion. Nature. 2004; 432(7014):226-30. DOI: 10.1038/nature03076. View

Tang X, Tang G, Ozcan S . Role of microRNAs in diabetes. Biochim Biophys Acta. 2008; 1779(11):697-701. PMC: 2643014. DOI: 10.1016/j.bbagrm.2008.06.010. View

Harrandah A, Fitzpatrick S, Smith M, Wang D, Cohen D, Chan E . MicroRNA-375 as a biomarker for malignant transformation in oral lesions. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016; 122(6):743-752.e1. DOI: 10.1016/j.oooo.2016.07.022. View

OBrien J, Hayder H, Zayed Y, Peng C . Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front Endocrinol (Lausanne). 2018; 9:402. PMC: 6085463. DOI: 10.3389/fendo.2018.00402. View

10.

Liu W, Zhao X, Zhang Y, Fang G, Xue Y . MicroRNA-375 as a potential serum biomarker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma. J Int Med Res. 2017; 46(3):975-983. PMC: 5972241. DOI: 10.1177/0300060517734114. View

11.

Seyhan A . microRNAs with different functions and roles in disease development and as potential biomarkers of diabetes: progress and challenges. Mol Biosyst. 2015; 11(5):1217-34. DOI: 10.1039/c5mb00064e. View

12.

Chen L, Li X, Zhao Y, Liu W, Wu H, Liu J . Down-regulated microRNA-375 expression as a predictive biomarker in non-small cell lung cancer brain metastasis and its prognostic significance. Pathol Res Pract. 2017; 213(8):882-888. DOI: 10.1016/j.prp.2017.06.012. View

13.

Zhao H, Guan J, Lee H, Sui Y, He L, Siu J . Up-regulated pancreatic tissue microRNA-375 associates with human type 2 diabetes through beta-cell deficit and islet amyloid deposition. Pancreas. 2010; 39(6):843-6. DOI: 10.1097/MPA.0b013e3181d12613. View

14.

Yan J, She Q, Shen X, Zhang Y, Liu B, Zhang G . Potential Role of MicroRNA-375 as Biomarker in Human Cancers Detection: A Meta-Analysis. Biomed Res Int. 2017; 2017:1875843. PMC: 5702930. DOI: 10.1155/2017/1875843. View

15.

. 2. Classification and Diagnosis of Diabetes: . Diabetes Care. 2018; 42(Suppl 1):S13-S28. DOI: 10.2337/dc19-S002. View

16.

Wang Q, Huang Z, Ni S, Xiao X, Xu Q, Wang L . Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer. PLoS One. 2012; 7(9):e44398. PMC: 3435315. DOI: 10.1371/journal.pone.0044398. View

17.

Asahara H . Current Status and Strategy of microRNA Research for Cartilage Development and Osteoarthritis Pathogenesis. J Bone Metab. 2016; 23(3):121-7. PMC: 5018604. DOI: 10.11005/jbm.2016.23.3.121. View

18.

Seyhan A, Nunez Lopez Y, Xie H, Yi F, Mathews C, Pasarica M . Pancreas-enriched miRNAs are altered in the circulation of subjects with diabetes: a pilot cross-sectional study. Sci Rep. 2016; 6:31479. PMC: 4997329. DOI: 10.1038/srep31479. View

19.

Alam K, Mo J, Han S, Park W, Kim H, Yun K . MicroRNA 375 regulates proliferation and migration of colon cancer cells by suppressing the CTGF-EGFR signaling pathway. Int J Cancer. 2017; 141(8):1614-1629. DOI: 10.1002/ijc.30861. View

20.

Zhang L, Jin W, Zheng J, Dai Y, Song Y, Ni H . MicroRNA-375 regulates proliferation and apoptosis of glioma cancer cells by inhibiting CTGF-EGFR signaling pathway. Bratisl Lek Listy. 2018; 119(1):17-21. DOI: 10.4149/BLL_2018_004. View